linjc16/ctgov huggingface dataset:
Retrospective Analysis of Spray Skin Treats for Severe Burns

Study Overview
=================
Brief Summary
-----------------
This study investigated the efficacy of novel approach spray skin for extensive severe burns treatment.

Detailed Description
-----------------
Burns are a global public health problem. This study investigated the efficacy of novel approach spray skin (autologous skin cell suspension combined with split-thickness skin grafting, STSG) for extensive severe burns treatment. We performed a real-world retrospective analysis of extensive burns patients (> 50% TBSA) from our hospital last 10 years.

Official Title
-----------------
A Real-world 10-year Single Center Experience With Spray Skin in the Treatment of Extensive Severe Burns

Conditions
-----------------
Morality, Skin Graft Complications

Intervention / Treatment
-----------------
* Procedure: spray skin
* Procedure: Control group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with > 50% TBSA Exclusion Criteria: died within 1 week after admission admitted to hospital more than 1 week after injury

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| experimental gourp<br>The patients who used the autologous skin cell suspension combined with skin grafting. | Procedure: spray skin<br>* The patients who used the autologous skin cell suspension combined with skin grafting.<br>|
| Control group<br>The patients who used split-thickness skin grafting. | Procedure: Control group<br>* The patients who used skin grafting.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| survival rate | Patient survival during hospitalization | through study completion, an average of 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complication of skin graft | the survival of grafting skin | the take rate in the postoperative day 30, 60, 90 | 
| length of hospital | The time during which the patient was hospitalized | through study completion, usually no more than 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
spray skin, severe burn, microskin grafting
Customized Crosslinking: Safety and Efficacy in an Epithelium-off Accelerated-pulsated Protocol for Thin Keratoconus

Study Overview
=================
Brief Summary
-----------------
The goal of this clinical trial is to document corneal ectasia stability in patients with keratoconus diagnosis treated with personalized cross linking energy. The main questions it aims to answer are: Is it effective while using personalized (reduced) energy? Is it safe for corneas thinner than 400 microns? Participants will be treated with personalized energy corneal cross linking and posteriorly, will attend subsequent follow-up consults

Official Title
-----------------
Customized Crosslinking: Safety and Efficacy in an Epithelium-off Accelerated-pulsated Protocol for Thin Keratoconus Corneas

Conditions
-----------------
Keratoconus

Intervention / Treatment
-----------------
* Procedure: Corneal Cross Linking


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Keratoconus diagnosed with corneal tomography/topography Thinnest point pachymetry below 400 microns Exclusion Criteria: Previous corneal cross linking history Corneal scars not allowing best corrected visual acuity of 20/100 or better Previous corneal hydrops history Psychomotor retardation history

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Personalized cross linking<br>Participants were treated with personalized energy cross linking according to their thinnest point corneal pachymetry | Procedure: Corneal Cross Linking<br>* Total fluence adapted to thinnest point pachymetry<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Keratometry stability | Stability documented by changes in keratometries (measured in diopters) obtained with corneal tomography, as well as uncorrected visual acuity observed in follow up consults | Baseline and 6 months | 
| Pachymetry stability | Stability documented by changes in pachymetry (measured in microns) obtained with corneal tomography | Baseline and 6 months | 
| Uncorrected visual acuity stability | Stability documented by changes in uncorrected visual acuity (measured in logarithm of the minimum angle of resolution) obtained on physical examiantion | Baseline, 72 hours, 1 week, 3 months and 6 months | 
| Corneal endothelium safety | Corneal endothelial cell count obtained by specular microscopy | Baseline, 72 hours, 1 week, 3 months and 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Customized, Cross-Linking, Progression
FoodImage 3 Laboratory

Study Overview
=================
Brief Summary
-----------------
The Laboratory Study will be conducted at PBRC and will include participants (N=25) from a wide array of social and economic groups will be recruited and trained on the use of the FoodImage app. Participants use the app to measure food waste (including foods with inedible parts) created during a simulated meal preparation setting, a simulated meal consumption setting with plate waste, and a simulated cabinet and refrigerator clean-out of spoiled and out-of-date foods, where the number of items and the amounts of waste for each task is randomly assigned across participants and blinded from the research staff evaluating images and coding data. These participants will denote the normal discard destination (I.e., garbage, sink/disposal, feed to animal, compost) for each item as if the waste had occurred in their own home.

Official Title
-----------------
Multiscale RECIPES (Resilient, Equitable, and Circular Innovations With Partnership and Education Synergies) for Sustainable Food Systems (FoodImage 3; FI3) Laboratory

Conditions
-----------------
Food Supply, Waste Management

Intervention / Treatment
-----------------
* Other: Controlled Conditions


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female, age 18-65 years Willing to be recontacted Exclusion Criteria: Refusal or unable to use an iPhone for study related purposes. Not willing to adhere to study procedures and study visit timelines. PBRC employee Any condition or circumstance that in the judgement of the PI could interfere with study participation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Laboratory<br>Simulated kitchen setting including purchase, prep, eating and cleanout | Other: Controlled Conditions<br>* Use of FoodImage app to take pictures of food and/or receipts.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Weight of Food Waste | Weight (g) | At Baseline Laboratory Study Visit |
Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Study Overview
=================
Brief Summary
-----------------
This is a multicenter, randomized, open-label phase II clinical trial. A total of 24 patients with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy were included. Subjects were treated with HRS-5965 for 12 weeks.

Official Title
-----------------
An Multicenter, Randomized, Open-label Proof of Concept Study to Assess the Efficacy, Safety of HRS-5965 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Conditions
-----------------
Paroxysmal Nocturnal Hemoglobinuria

Intervention / Treatment
-----------------
* Drug: HRS-5965 tablets


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of PNH confirmed by flow cytometry with clone size ≥ 10%. Have not received complement inhibitor therapy ; LDH > 1.5×ULN; Hemoglobin level < 10 g/dL. Exclusion Criteria: Known or suspected hereditary or acquired complement deficiency; Patients with laboratory evidence of bone marrow failure (reticulocytes <100x109/L; platelets <30x109/L; neutrophils <0.5x109/L); Presence or suspicion of a systemic active bacterial, viral, or fungal infection (based on judgment of the investigator) within 2 weeks prior to the first dose of HRS-5965; History of infection with capsular bacteria (e.g., meningococcus, pneumococcus, etc.) Positive of HIV, HBsAg or HCVAb.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Treatment group A<br> | Drug: HRS-5965 tablets<br>* HRS-5965 tablets for 12 weeks<br>|
| Experimental: Treatment group B<br> | Drug: HRS-5965 tablets<br>* HRS-5965 tablets for 12 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in hemoglobin. |  | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in LDH. |  | 12 weeks | 
| Changes in haptoglobin. |  | 12 weeks | 
| Changes in bilirubin. |  | 12 weeks | 
| Changes in reticulocyte counts. |  | 12weeks | 
| Changes in C3 complement fragment deposition. |  | 12 week | 
| Percentage of patients who did not receive a blood transfusion. |  | 12 weeks | 
| Number of RBC units of transfused. |  | 12weeks | 
| Incidence and severity of adverse events |  | 16 weeks | 
| Incidence of thromboembolic events. |  | 16 weeks | 
| Plasma concentration of HRS-5965. |  | 12 weeks |
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer

Study Overview
=================
Brief Summary
-----------------
The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in resected pancreatic cancer. The main questions it aims to answer are: prognostic value of baseline MRD; the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood derived from participants will be obtained for MRD test before adjuvant chemotherapy initiation and at the first imaging assessment after chemotherapy.

Official Title
-----------------
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer

Conditions
-----------------
Pancreatic Cancer, Resectable Carcinoma

Intervention / Treatment
-----------------
* Drug: Later-line therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with pancreatic cancer who had undergone curative-intent surgery (R0 or R1 resection); both sexes, age ≥18 years old; ECOG performance status score ≤2; the expected survival time was ≥3 months. Exclusion Criteria: a known diagnosis of pancreatic cancer other than ductal adenocarcinoma; treated with any systemic antitumor treatment before first-line chemotherapy onset; died or lost to follow-up within one month after the initiation of adjuvant chemotherpay; combined with other primary malignances.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MRD-guided<br>Patients with elevated MRD from baseline at the first imaging assessment but without radiographic progressive disease will receive a later-line therapy. | Drug: Later-line therapy<br>* Another chemotherapy regimen, targeted therapy, or immunotherapy<br>|
| No Intervention: Routine treatment<br>Patients with elevated MRD from baseline at the first imaging assessment but without radiographic progressive disease will continued their current therapy. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease-free survival | The date of adjuvant chemotherpay initiation to tumor recurrence, local-regional or distant metastases, or death due to any cause. | Baseline until death from any cause (up to approximately 36 months) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | The date of adjuvant chemotherpay initiation to death due to any cause. | Baseline until death from any cause (up to approximately 60 months) |
Exercise Oxygen Kinetic and Cardiac Output in Hypertrophic Cardiomyopathy

Study Overview
=================
Brief Summary
-----------------
Fatigue and dyspnea that reduce exercise performance are common symptoms in patients with hypertrophic cardiomyopathy. Since the cause of this functional limitation has not yet been described, this study aims to evaluate the cardiopulmonary parameters measured at cardiopulmonary exercise test in combination with those obtained by non-invasive measurement of cardiac output by impedance (Physioflow) and echocardiography. These results will help to better define the mechanisms underlying limitation in these patients, also in relation to the degree of LVOT obstruction. The aim of the present study is to assess the cardiopulmonary response to exercise in patients with hypertrophic cardiomyopathy, based on the degree of LVOT obstruction, by adding non-invasive measurement of cardiac output by Physioflow and echocardiographic parameters to the cardiopulmonary exercise test parameters associated with stroke volume and cardiac output (ie. VO2/WR, O2pulse) Consecutive patients with a previous diagnosis of hypertrophic cardiomyopathy on optimised medical therapy will be enrolled to perform a cardiopulmonary exercise test with simultaneous measurement of cardiac output and an exercise echocardiogram for clinical routine.

Official Title
-----------------
Exercise Oxygen Kinetic and Cardiac Output in Hypertrophic Cardiomyopathy: a Multicenter Prospective Cardiopulmonary Exercise Testing Study

Conditions
-----------------
Cardiopulmonary Exercise Test, Hypertrophic Cardiomyopathy, Cardiac Output Measurement

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hypertrophic cardiomyopathy diagnosis Exclusion Criteria: use of long-term oxygen therapy; presence of comorbidities affecting the ability to perform cardiopulmonary exercise test or interfering with exercise performance; concomitant at least moderate chronic obstructive pulmonary disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cardiac output measurement | Evaluate cardiopulmonary exercise test parameters associated with stroke volume and cardiac output (ie. VO2/WR, O2pulse) with the addition of non-invasive measurement of cardiac output using Physioflow. | immediately after the evaluation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation with echocardiographic variables | Correlate functional and metabolic data with echocardiographic variables collected at rest and under stress. | immediately after the evaluation |
Risk of Chronic Post-surgical Pain After TKA

Study Overview
=================
Brief Summary
-----------------
Chronic post-surgical pain (CPSP) is a common surgical complication. The role of timing in the development of CPSP after bilateral total knee arthroplasty (BTKA) is not well studied. We aimed to compare the occurrence of CPSP in patients who underwent simultaneous or staged BTKA without discharge between procedures.

Official Title
-----------------
Risk of Chronic Post-surgical Pain After Simultaneous Versus Staged Bilateral Knee Arthroplasty: A Retrospective Study With Propensity Score Matching

Conditions
-----------------
Bilateral Total Knee Chronic Pain Following Arthroplasty

Intervention / Treatment
-----------------
* Procedure: Simultaneous BTKA
* Procedure: Staged BTKA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: From October 12, 2012 to December 2, 2021, patients who underwent bilateral or staged knee replacement surgery during a single hospitalization under Professor Lee Woo-seok at the Department of Orthopedics at Gangnam Severance Hospital due to bilateral knee arthritis. Exclusion Criteria: Patients whose post-operative pain information cannot be confirmed through outpatient visit records 1 year after surgery Those who have undergone surgery other than knee arthritis surgery within 1 year after surgery
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Simultaneous BTKA<br>Simultaneous BTKA | Procedure: Simultaneous BTKA<br>* Simultaneous BTKA<br>|
| Staged BTKA<br>Staged BTKA | Procedure: Staged BTKA<br>* Staged BTKA<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Chronic post-surgical pain at one year follow up | Numeric rating scale (0: no pain, 10: extreme pain) | at one year follow up after surgery |
Risk Identification Factors for Pulmonary Function Impairment in AIDS Patients Recovered From Severe Pneumonia

Study Overview
=================
Brief Summary
-----------------
Screening for risk factors related to lung function impairment in patients who have recovered from AIDS with severe pneumonia, to provide clinical evidence for early identification and intervention of lung function damage in this population.

Detailed Description
-----------------
This is a prospective, single-center, non-randomized, clinical observational cohort study. It involves monitoring lung function at discharge (baseline, 0w), and at the 4th, 8th, 12th, 24th, and 48th weeks in patients recovering from severe pneumonia with AIDS. Basic demographic data, HIV RNA quantification, routine blood tests, blood biochemistry, arterial blood gas results, oxygenation index, immune function (CD3+, CD4+, CD8+ T cell counts), and imaging studies are also collected. Multifactorial logistic regression analysis is used to screen for clinical predictors of lung function decline in patients recovering from severe pneumonia

Official Title
-----------------
Study on Risk Identification Factors for Lung Function Impairment in AIDS Patients Recovered From Severe Pneumonia

Conditions
-----------------
AIDS, Pneumonia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed HIV infection; Progression to the AIDS stage: CD4+ count <200 cells/µL and/or occurrence of opportunistic infections associated with AIDS; Age between 18 to 65 years; Meet the diagnostic criteria for severe pneumonia, with reference to the 2021 treatment guidelines for community-acquired pneumonia developed by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA). Exclusion Criteria: Concurrent central nervous system lesions, severe liver disease, or cirrhosis; Concurrent AIDS-related or non-related tumors; Women who are pregnant or breastfeeding; Presence of serious underlying diseases such as heart, lung, liver, kidney, etc.; Alcohol abuse or drug use; The researcher believes that the overall condition of the subject affects the evaluation and completion of the trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Obstructive Ventilatory Dysfunction | FEV1(Forced Expiratory Volume in One Second )to FVC (Forced Vital Capacity ) Ratio | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| FEV1 | FEV1 decrease of ≥100 mL | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AIDS, Severe pneumonia, Lung function, Predictive factors